Global elimination of trachoma: how frequently should we administer mass chemotherapy?
- PMID: 10229236
- DOI: 10.1038/8451
Global elimination of trachoma: how frequently should we administer mass chemotherapy?
Abstract
The World Health Organization has recommended repeat mass drug administration as part of their global initiative to eliminate blinding trachoma by the year 2020. The efficacy of repeat treatment will be tested empirically, but the results will not be available for many years, and recommendations for the necessary frequency of treatment are needed immediately. We have developed a mathematical model that uses available epidemiological data from a variety of countries. We recommend, based on our analysis, that in areas where trachoma is moderately prevalent (<35% in children), it should be treated annually, but hyperendemic areas (>50% in children), it should be treated biannually.
Comment in
-
Towards the global elimination of trachoma.Nat Med. 1999 May;5(5):492-3. doi: 10.1038/8376. Nat Med. 1999. PMID: 10229224 No abstract available.
Similar articles
-
Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1492-7. doi: 10.1167/iovs.06-0625. Invest Ophthalmol Vis Sci. 2007. PMID: 17389476
-
Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.Ophthalmic Epidemiol. 2011 Feb;18(1):20-9. doi: 10.3109/09286586.2010.545500. Ophthalmic Epidemiol. 2011. PMID: 21275593 Clinical Trial.
-
Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali.Acta Trop. 2007 Jan;101(1):40-53. doi: 10.1016/j.actatropica.2006.12.003. Epub 2006 Dec 16. Acta Trop. 2007. PMID: 17239332
-
Trachoma and antibiotic use: the 'A' in SAFE.Expert Rev Anti Infect Ther. 2012 Jan;10(1):75-83. doi: 10.1586/eri.11.150. Expert Rev Anti Infect Ther. 2012. PMID: 22149616 Review.
-
Rationale for mass antibiotic distribution for trachoma elimination.Int Ophthalmol Clin. 2002 Winter;42(1):85-92. doi: 10.1097/00004397-200201000-00012. Int Ophthalmol Clin. 2002. PMID: 12189619 Review. No abstract available.
Cited by
-
Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2303. doi: 10.1371/journal.pntd.0002303. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23875038 Free PMC article.
-
Coinfection Dynamics of Two Diseases in a Single Host Population.J Math Anal Appl. 2016 Oct 1;442(1):171-188. doi: 10.1016/j.jmaa.2016.04.039. Epub 2016 Apr 19. J Math Anal Appl. 2016. PMID: 27667856 Free PMC article.
-
Current problems of perinatal Chlamydia trachomatis infections.J Immune Based Ther Vaccines. 2004 Feb 13;2(1):4. doi: 10.1186/1476-8518-2-4. J Immune Based Ther Vaccines. 2004. PMID: 14962349 Free PMC article.
-
The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.Parasit Vectors. 2017 Dec 28;10(1):624. doi: 10.1186/s13071-017-2566-x. Parasit Vectors. 2017. PMID: 29282126 Free PMC article.
-
Active trachoma two years after three rounds of azithromycin mass treatment in Cheha District Gurage Zone, Southern Ethiopia.BMC Pediatr. 2013 Dec 1;13:199. doi: 10.1186/1471-2431-13-199. BMC Pediatr. 2013. PMID: 24289535 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources